Table 1.
Meta-analysis of glucocorticoid therapy in IVF cycles
| Study | Journal (year) | Included RCT (n, criteria) | Main outcome | Subgroup analysis |
|---|---|---|---|---|
| Boomsma et al. [74] | Cochrane Database Syst Rev (2007) | 13 RCTs (1,759 couples, none) | LBR (OR, 1.21; 95% CI, 0.67–2.19; NS; 3 RCTs) | PR per couple in IVF (OR, 1.5; 95% CI, 1.05–2.13; p=0.02; 6 RCTs) |
| OPR (OR, 1.15; 95% CI, 0.76–1.75; NS; 3 RCTs) | ||||
| Boomsma et al. [74] | Cochrane Database Syst Rev (2012) | 14 RCTs (1,879 couples, none) | LBR (OR, 1.21; 95% CI, 0.67–2.19; NS; 3 RCTs) | PR per couple in IVF (OR, 1.5; 95% CI, 1.05–2.13; p=0.02; 6 RCTs) |
| OPR: (OR, 1.15; 95% CI, 0.76–1.75; NS; 3 RCTs) | ||||
| Dan et al. [75] | Am J Reprod Immunol (2015) | 5 RCTs (828 couples, unexplained recurrent miscarriage) | LBR (OR, 1.58; 95% CI, 1.23–2.02; p=0.0003; 2 RCTs) | MR (OR, 0.5; 95% CI, 0.31–0.81; p=0.005; 2 RCTs) |
| OPR (OR, 7.63; 95% CI, 3.71–15.69; p<0.00001; 1 RCTs) | ||||
| Kalampokas et al. [76] | Cochrane Database Syst Rev (2017) | 4 RCTs (416 couples, none) | LBR (OR, 1.08; 95% CI, 0.45–2.58; NS; 2 RCTs) | |
| OPR (OR, 1.69; 95% CI, 0.98–2.9; NS; 2 RCTs) | ||||
| Achilli et al. [77] | Fertil Steril (2018) | 2 RCTs (202 couples, recurrent pregnancy loss) | OPR (OR, 1.12; 95% CI, 0.75–1.67; NS; 2 RCTs) | |
| Zhou et al. [78] | Medicine (2021) | 3 RCTs (237 couples, anti-thyroid antibody positive) | LBR (OR, 3.19; 95% CI, 1.13–9.04; p=0.03; 2 RCTs) | MR (OR, 0.62; 95% CI, 0.09–4.32; NS; 3 RCTs) |
| OPR (OR, 4.63; 95% CI, 2.23–9.58; p<0.0001; 3 RCTs) |
IVF, in vitro fertilization; RCT, randomized controlled trial; LBR, live birth rate; OR, odds ratio; CI, confidence interval; NS, not significant; PR, pregnancy rate; OPR, ongoing pregnancy rate; MR, miscarriage rate.